China Issues 15th Five-Year Pharma Plan Targeting 20% Annual Growth for Innovative Drugs
On September 18, ten Chinese government departments jointly released the "15th Five-Year Plan for the Development of the Pharmaceutical Industry," setting 2030 targets including operating revenue exceeding 3.5 trillion yuan for large-scale pharmaceutical enterprises, an average annual growth rate of over 20% for the innovative drug sector, and at least five products with global annual sales exceeding $1 billion. The plan designates the pharmaceutical industry as a "national emerging pillar industry" for the first time, emphasizes AI-driven drug development, and targets first-in-class drugs to account for over 25% of global share. Following the announcement, A-share innovative drug stocks and ETFs surged.
IllustrationEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Common ground
- Both agree that Western pharmaceutical monopolies have exploited the Global South with high drug prices and patent protections.
- Both recognize that China's 15th Five-Year Plan aims to make the country a global leader in innovative drug development.
- Both see the plan as a strategic move to challenge the current Western-dominated pharmaceutical system.
Points of contention
- The Eastern Agent sees the plan as a net positive for global health equity, while the Regional Agent argues it's primarily about Chinese dominance, not solidarity.
- The Eastern Agent believes Chinese state control can enforce price controls and benefit the Global South, but the Regional Agent points to examples like Sinovac in Brazil where prices were raised mid-pandemic.
- The Regional Agent demands binding commitments to technology transfer and local production in developing nations, while the Eastern Agent says such partnerships are already happening through Belt and Road initiatives.
Blind spots
- Neither side fully addresses how local corruption and weak supply chains in the Global South might undermine access to affordable drugs, regardless of who produces them.
- Both overlook the lack of binding price caps or licensing requirements in the plan for low-income countries, focusing instead on broader strategic or humanitarian claims.
- The debate ignores the role of international regulatory bodies and multilateral agreements in ensuring fair distribution and pricing.
WorldAttention’s read
This debate reveals a deep divide between viewing China's pharmaceutical plan as a necessary challenge to Western monopoly or as a new form of dominance. Both sides agree that the current system has failed the Global South, but they disagree on whether China's approach will truly empower developing nations or just swap one master for another. The Eastern Agent argues that competition from Chinese drugs will lower prices and force Western firms to negotiate, while the Regional Agent insists that without binding commitments to technology transfer and price controls, the mother in Mogadishu will still be at the mercy of whoever holds the patent. Ultimately, the plan is a strategic move for Chinese interests, but its impact on global health equity depends on whether it leads to genuine local capacity-building or just a new monopoly with a different flag.
Reporting timeline
China's Innovative Drug Sector Sees Milestones, Shifts to Profit-Driven Growth
This article from Investment Times, published on Tencent Stock, analyzes the recent achievements and future trends in China's innovative drug industry. It highlights that in the first half of 2026, China approved 38 Class 1 innovative drugs, including 11 with new targets and mechanisms, all domestically developed. Several 'global-first' drugs have been approved, marking what analysts describe as a structural turning point from a follower to a standard-setter. The core driver of the industry has shifted from R&D expectations to the realization of profit inflection points and global innovation asset value. Key financial changes include multiple biotech firms turning profitable, rising innovative drug revenue share at large pharma companies, and diversified overseas partnerships. The first AI-assisted drug, Yisitevir Hydrochloride Tablets, was approved after only 3.5 years of development, signaling commercial AI pharma. The '15th Five-Year Plan' for the pharmaceutical industry, released on September 18, 2026, sets a target for the innovative drug sector to grow at an average annual rate of over 20% and for China's first-in-class drugs to account for no less than 25% of the global share by 2030. The article concludes by promoting two related ETFs from Yinhua Fund.
China's Ten Ministries Issue 15th Five-Year Plan to Boost Innovative Drug R&D
The article reports on the performance of several healthcare and innovative drug indices on the Hong Kong and mainland Chinese stock markets as of midday trading. It highlights a new policy initiative: China's Ministry of Industry and Information Technology, along with nine other departments, jointly issued the '15th Five-Year Plan for the Development of the Pharmaceutical Industry.' The plan sets ambitious targets for 2030, including an average R&D investment intensity of over 10% for listed pharmaceutical companies, a leading global position in the number of first-in-human clinical trial pipelines and new drug approvals, and first-in-class (FIC) drugs accounting for over 25% of the global share. Industry analysts cited in the article believe this policy will help address the current issue of homogeneity in China's innovative drug sector, pushing companies to focus on clinical value and unmet medical needs rather than following trends.
Read sourceChina's Innovative Drug ETFs Rise as '15th Five-Year' Plan Designates Pharma as Pillar Industry
Innovative drug ETFs in China's A-share market rose broadly, with the innovative drug index posting a 'six consecutive gains' streak. The rally follows the official release of the '15th Five-Year Plan' for the pharmaceutical industry, which for the first time designates the sector as a 'national emerging pillar industry' and sets a core goal for 2030 to keep China's biomedical R&D and application among the world's top tier. Recent institutional research reports note that the plan for the first time lists 'precision diagnosis and treatment' as an independent section, targets over 200 innovative medical device approvals within five years, and systematically deploys frontier directions including AI-driven drug development, radionuclide diagnostics and therapy, and brain-computer interfaces. Analysts believe the policy represents a comprehensive upgrade in strategic positioning, quantitative targets, and detailed pathways, far exceeding the previous '14th Five-Year Plan'. The research reports state that innovative drug companies with FIC/BIC pipelines and international clinical capabilities, as well as CXO firms deeply integrated into global innovation, will directly benefit from accelerated industrialization and order expansion. AI drug development platforms with real pipeline progress are also expected to gain both capital and policy recognition.
Read sourceShow 17 older updatesHide older updates
China's Innovative Drug ETFs Rise as New Five-Year Plan Boosts Sector
Innovative drug ETFs in China's A-share market saw broad gains, with the Sci-Tech Innovation Drug ETFs from both Harvest and Guotai rising nearly 2%. The innovative drug index extended its winning streak to six consecutive sessions. The catalyst was the official release of the pharmaceutical industry's '15th Five-Year Plan,' which for the first time designates the pharmaceutical industry as a 'national emerging pillar industry' and sets a core target for China's biomedical R&D and application to rank among the world's top by 2030. Recent institutional research reports note that the plan elevates 'precision diagnosis and treatment' to an independent section for the first time, targets the launch of over 200 innovative medical devices within five years, and systematically deploys frontier areas such as AI-driven drug development, nuclide-based diagnostics and therapy, and brain-computer interfaces. Analysts believe the policy represents a comprehensive upgrade in strategic positioning, quantitative targets, and detailed pathways, far exceeding the previous five-year plan. The reports indicate that innovative drug companies with first-in-class or best-in-class pipelines and international clinical capabilities, as well as CXO firms deeply integrated into the global innovation division of labor, will directly benefit from accelerated industrialization and expanded orders. AI drug development platforms with real pipeline progress are also expected to gain both capital and policy recognition.
Read sourceChina Innovative Drug ETFs Rally as New Five-Year Plan Boosts Sector
Innovative drug exchange-traded funds (ETFs) in China saw broad gains, with the Sci-Tech Innovation Drug ETFs from both Harvest and Guotai rising nearly 2%. The innovative drug index extended its winning streak to six consecutive sessions. The rally follows the official release of the pharmaceutical industry's 15th Five-Year Plan, which for the first time designates the pharmaceutical industry as a 'national emerging pillar industry' and sets a core target for China's biomedical R&D and application to rank among the world's top by 2030. Recent institutional research reports highlight that the plan elevates 'precision diagnostics' to an independent section for the first time, targets over 200 innovative medical device approvals within five years, and systematically deploys frontier areas such as AI-driven drug development, nuclide diagnostics and therapy, and brain-computer interfaces. Analysts believe the policy represents a comprehensive upgrade in strategic positioning, quantitative targets, and detailed pathways, far exceeding the previous 14th Five-Year Plan. The reports note that innovative drug companies with first-in-class or best-in-class pipelines and international clinical capabilities, as well as contract research organizations (CXOs) deeply integrated into global innovation, will directly benefit from accelerated industrialization and expanded orders. AI drug development platforms with real pipeline progress are also expected to gain both capital and policy recognition.
Read sourceChina's Innovative Drug ETFs Rally as New Five-Year Plan Boosts Sector
Innovative drug exchange-traded funds (ETFs) in China saw broad gains, with the Sci-Tech Innovation Drug ETF from both Harvest and Guotai rising nearly 2%. The innovative drug index has risen for six consecutive trading days. This rally follows the official release of the pharmaceutical industry's '15th Five-Year Plan' (2026-2030), which for the first time designates the pharmaceutical industry as a 'national emerging pillar industry' and sets a core goal for China's biomedical R&D and application to rank among the world's top by 2030. Recent institutional research reports highlight that the plan, for the first time, lists 'precision diagnosis and treatment' as an independent section, targets the launch of over 200 innovative medical devices within five years, and systematically deploys frontier areas such as AI-driven drug development, nuclide-based diagnostics and therapy, and brain-computer interfaces. Analysts believe the policy represents a comprehensive upgrade in strategic positioning, quantitative targets, and detailed pathways, far exceeding the intensity of the '14th Five-Year Plan'. The reports indicate that innovative drug companies with first-in-class (FIC) or best-in-class (BIC) pipelines and international clinical capabilities, as well as contract research organizations (CXOs) deeply integrated into global innovation, will directly benefit from accelerated industrialization and expanded orders. AI drug development platforms with real pipeline progress are also expected to gain both capital and policy recognition.
Read sourceChina Innovative Drug ETFs Rally as New Five-Year Plan Boosts Sector
Innovative drug exchange-traded funds (ETFs) in China saw broad gains, with the Sci-Tech Innovation Drug ETF from both Harvest and Guotai rising nearly 2%. The innovative drug index extended its winning streak to six consecutive sessions. The rally follows the official release of the pharmaceutical industry's 15th Five-Year Plan, which for the first time designates the pharmaceutical industry as a 'national emerging pillar industry' and sets a core target for China's biomedical R&D and application to rank among the world's top by 2030. Recent institutional research reports highlight that the plan introduces a standalone section on 'precision diagnosis and treatment,' targets over 200 innovative medical device approvals within five years, and systematically deploys frontier areas such as AI drug development, nuclide diagnostics and therapy, and brain-computer interfaces. Analysts believe the policy represents a comprehensive upgrade in strategic positioning, quantitative targets, and detailed pathways, far exceeding the 14th Five-Year Plan. The reports note that innovative drug companies with first-in-class or best-in-class pipelines and international clinical capabilities, as well as CXO firms deeply integrated into global innovation, will directly benefit from accelerated industrialization and order expansion. AI drug development platforms with real pipeline progress are also expected to gain both capital and policy recognition.
Read sourceChina Innovative Drug ETFs Rally as New Five-Year Plan Boosts Sector
Innovative drug exchange-traded funds (ETFs) in China saw broad gains, with the Sci-Tech Innovation Drug ETF from both Harvest and Guotai rising nearly 2%. The innovative drug index extended its winning streak to six consecutive sessions. The rally follows the official release of the pharmaceutical industry's 15th Five-Year Plan, which for the first time designates the pharmaceutical industry as a 'national emerging pillar industry' and sets a core target for China's biomedical research and development application to rank among the world's top by 2030. Recent institutional research reports highlight that the plan introduces a standalone section on 'precision diagnosis and treatment,' targets over 200 innovative medical device approvals within five years, and systematically deploys frontier areas such as AI drug discovery, nuclide diagnostics and therapy, and brain-computer interfaces. Analysts believe the policy represents a comprehensive upgrade in strategic positioning, quantitative targets, and detailed pathways, far exceeding the 14th Five-Year Plan. The reports note that innovative drug companies with first-in-class/best-in-class pipelines and international clinical capabilities, as well as contract research organizations (CXOs) deeply integrated into global innovation, will directly benefit from accelerated industrialization and order expansion. AI drug discovery platforms with real pipeline progress are also expected to gain both capital and policy recognition.
Read sourceChina Innovative Drug ETFs Rally as New Plan Elevates Pharma to Pillar Industry
Innovative drug exchange-traded funds (ETFs) in China saw broad gains, with the Sci-Tech Innovation Drug ETF (Huatai-PineBridge) and the Sci-Tech Innovation Drug ETF (China Asset Management) both rising nearly 2%. The innovative drug index extended its winning streak to six consecutive sessions. The catalyst was the official release of the pharmaceutical industry's '15th Five-Year Plan,' which for the first time designates the pharmaceutical industry as a 'national emerging pillar industry' and sets a core target for China's biomedical R&D and application to rank among the world's top by 2030. Recent institutional research reports note that the plan introduces a standalone section on 'precision diagnosis and treatment,' targets the launch of over 200 innovative medical devices within five years, and systematically deploys frontier areas such as AI-driven drug development, radionuclide diagnostics and therapy, and brain-computer interfaces. Analysts assess that the policy represents a comprehensive upgrade in strategic positioning, quantitative targets, and specific pathways, far exceeding the intensity of the 14th Five-Year Plan. The reports indicate that innovative drug companies with first-in-class or best-in-class pipelines and global clinical capabilities, as well as contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) deeply integrated into global innovation networks, will directly benefit from accelerated industrialization and expanded orders. AI drug development platforms with real pipeline progress are also expected to gain both capital and policy recognition.
Read sourceChina Innovative Drug ETFs Rally as New Five-Year Plan Boosts Sector
Innovative drug exchange-traded funds (ETFs) in China saw broad gains, with the Sci-Tech Innovation Drug ETF from both Harvest and China Asset Management rising nearly 2%. The innovative drug index extended its winning streak to six consecutive sessions. The rally follows the official release of the pharmaceutical industry's 15th Five-Year Plan, which for the first time designates the pharmaceutical industry as a 'national emerging pillar industry' and sets a core target for China's biomedical R&D and application to rank among the world's top by 2030. Recent institutional research reports highlight that the plan introduces a standalone section on 'precision diagnosis and treatment,' targets over 200 innovative medical device approvals within five years, and systematically deploys frontier areas such as AI-driven drug development, nuclide diagnostics and therapy, and brain-computer interfaces. Analysts believe the policy represents a comprehensive upgrade in strategic positioning, quantitative targets, and detailed pathways, far exceeding the previous Five-Year Plan. The reports indicate that innovative drug companies with first-in-class or best-in-class pipelines and international clinical capabilities, as well as contract research organizations (CXOs) deeply integrated into global innovation, will directly benefit from accelerated industrialization and expanded orders. AI drug development platforms with real pipeline progress are also expected to gain both capital and policy recognition.
Read sourceChina's Innovative Drug ETFs Rise as 15th Five-Year Plan Boosts Sector
Innovative drug ETFs in China's A-share market saw broad gains, with the Sci-Tech Innovation Drug ETF (Huatai-PineBridge) and Sci-Tech Innovation Drug ETF (Guotai) both rising nearly 2%. The innovative drug index extended its winning streak to six consecutive sessions. The catalyst was the official release of the pharmaceutical industry's '15th Five-Year Plan,' which for the first time designates the pharmaceutical industry as a 'national emerging pillar industry' and sets a core goal of achieving a world-leading position in biomedical R&D and application by 2030. Recent institutional research reports note that the plan introduces a standalone section on 'precision diagnosis and treatment,' targets the approval of over 200 innovative medical devices within five years, and systematically deploys frontier areas such as AI-driven drug development, nuclide-based diagnostics and therapy, and brain-computer interfaces. Analysts believe the policy represents a comprehensive upgrade in strategic positioning, quantitative targets, and specific pathways, far exceeding the intensity of the 14th Five-Year Plan. The reports indicate that innovative drug companies with first-in-class or best-in-class pipelines and global clinical capabilities, as well as CRO/CDMO firms deeply integrated into global innovation networks, will directly benefit from accelerated industrialization and expanded orders. AI drug development platforms with real pipeline progress are also expected to gain both capital and policy recognition.
Read sourceChina Innovative Drug ETFs Rally as New Five-Year Plan Boosts Sector
Innovative drug exchange-traded funds (ETFs) in China rose broadly, with the Sci-Tech Innovation Drug ETF from both Harvest Fund and China Asset Management gaining nearly 2%. The innovative drug index extended its winning streak to six consecutive sessions. The rally follows the official release of the pharmaceutical industry's 15th Five-Year Plan, which for the first time designates the pharmaceutical industry as a 'national emerging pillar industry' and sets a core target for China's biomedical R&D and application to rank among the world's top by 2030. Recent institutional research reports highlight that the plan introduces a standalone section on 'precision diagnosis and treatment,' targets over 200 innovative medical device approvals within five years, and systematically deploys frontier areas such as AI-driven drug development, nuclide-based diagnostics and therapy, and brain-computer interfaces. Analysts believe the policy represents a comprehensive upgrade in strategic positioning, quantitative targets, and detailed pathways, far exceeding the intensity of the 14th Five-Year Plan. The reports note that innovative drug companies with first-in-class or best-in-class pipelines and global clinical capabilities, as well as contract research organizations (CXOs) deeply integrated into global innovation, will directly benefit from accelerated industrialization and expanded orders. AI drug development platforms with real pipeline progress are also expected to gain both capital and policy recognition.
Read sourceChina Innovative Drug ETFs Rally as New Five-Year Plan Boosts Sector
Innovative drug exchange-traded funds (ETFs) in China rose broadly, with the Sci-Tech Innovation Drug ETF (Huatai-PineBridge) and Sci-Tech Innovation Drug ETF (Guotai) both gaining nearly 2%. The innovative drug index extended its winning streak to six consecutive sessions. The rally follows the official release of the pharmaceutical industry's 15th Five-Year Plan, which for the first time designates the pharmaceutical industry as a 'national emerging pillar industry' and sets a core goal of achieving a world-leading position in biomedical R&D and application by 2030. Recent institutional research reports note that the plan introduces a standalone section on 'precision diagnosis and treatment,' targets the launch of over 200 innovative medical devices within five years, and systematically deploys frontier areas such as AI-driven drug development, nuclide-based diagnostics and therapy, and brain-computer interfaces. Analysts believe the policy represents a comprehensive upgrade in strategic positioning, quantitative targets, and specific pathways, far exceeding the intensity of the 14th Five-Year Plan. The reports indicate that innovative drug companies with first-in-class or best-in-class pipelines and international clinical capabilities, as well as contract research organizations (CROs) deeply integrated into global innovation, will directly benefit from accelerated industrialization and expanded orders. AI drug development platforms with real pipeline progress are also expected to gain both capital and policy recognition.
Read sourceChina Innovative Drug ETFs Rally as New Five-Year Plan Boosts Sector
Innovative drug exchange-traded funds (ETFs) in China saw broad gains, with the Sci-Tech Innovation Innovative Drug ETFs from both Harvest and Guotai rising nearly 2%. The innovative drug index extended its winning streak to six consecutive sessions. The rally follows the official release of the pharmaceutical industry's 15th Five-Year Plan, which for the first time designates the pharmaceutical industry as a 'national emerging pillar industry' and sets a core target for China's biomedical R&D applications to rank among the world's top by 2030. Recent institutional research reports highlight that the plan introduces a standalone section on 'precision diagnosis and treatment,' targets over 200 innovative medical device approvals within five years, and systematically deploys frontier areas such as AI drug development, nuclide diagnostics and therapy, and brain-computer interfaces. Analysts believe the policy represents a comprehensive upgrade in strategic positioning, quantitative targets, and specific pathways, far exceeding the previous Five-Year Plan. The reports indicate that innovative drug companies with first-in-class or best-in-class pipelines and international clinical capabilities, as well as contract research organizations (CXOs) deeply integrated into global innovation, will directly benefit from accelerated industrialization and expanded orders. AI drug development platforms with real pipeline progress are also expected to gain both capital and policy recognition.
Read sourceChina's Innovative Drug ETFs Rise as New Five-Year Plan Boosts Sector
Innovative drug ETFs in China saw broad gains, with the Sci-Tech Innovation Drug ETF (Huatai-PineBridge) and the Sci-Tech Innovation Drug ETF (China Asset Management) both rising nearly 2%. The innovative drug index has risen for six consecutive trading days. The surge follows the official release of the pharmaceutical industry's '15th Five-Year Plan,' which for the first time designates the pharmaceutical industry as a 'national emerging pillar industry' and sets a core goal for China's biomedical R&D and application to rank among the world's top by 2030. Recent institutional research reports note that the plan for the first time lists 'precision diagnosis and treatment' as an independent section, targets the launch of over 200 innovative medical devices within five years, and systematically deploys frontier areas such as AI drug development, nuclide diagnostics and therapy, and brain-computer interfaces. Analysts believe the policy represents a comprehensive upgrade in strategic positioning, quantitative targets, and detailed pathways, far exceeding the intensity of the '14th Five-Year Plan.' The reports indicate that innovative drug companies with FIC/BIC pipelines and international clinical capabilities, as well as CXO firms deeply serving the global innovation division of labor, will directly benefit from accelerated industrialization and expanded orders. AI drug development platforms with real pipeline progress are also expected to gain both capital and policy recognition.
Read sourceChina Innovative Drug ETFs Rally as New Five-Year Plan Boosts Sector
Innovative drug exchange-traded funds (ETFs) in China saw broad gains, with the Sci-Tech Innovation Drug ETF (Huatai-PineBridge) and Sci-Tech Innovation Drug ETF (China Asset Management) both rising nearly 2%. The innovative drug index extended its winning streak to six consecutive sessions. The rally follows the official release of the pharmaceutical industry's 15th Five-Year Plan, which for the first time designates the pharmaceutical industry as a 'national emerging pillar industry' and sets a core target for China's biomedical R&D and application to rank among the world's top tier by 2030. Recent institutional research reports cited in the article note that the plan introduces a standalone section on 'precision diagnosis and treatment,' targets the approval of over 200 innovative medical devices within five years, and systematically deploys frontier areas such as AI-driven drug development, radionuclide diagnostics and therapy, and brain-computer interfaces. The reports assess that the policy represents a comprehensive upgrade in strategic positioning, quantitative targets, and specific pathways, far exceeding the intensity of the 14th Five-Year Plan. Analysts state that innovative drug companies with first-in-class or best-in-class pipelines and international clinical capabilities, as well as contract research organizations (CXOs) deeply integrated into global innovation, will directly benefit from accelerated industrialization and expanded orders. AI drug development platforms with real pipeline progress are also expected to gain both capital and policy recognition.
Read sourceChina Innovative Drug ETFs Rally as New Five-Year Plan Boosts Sector
Innovative drug exchange-traded funds (ETFs) in China saw broad gains, with the Sci-Tech Innovation Drug ETF from both Harvest and Guotai rising nearly 2%. The innovative drug index extended its winning streak to six consecutive sessions. The rally follows the official release of the pharmaceutical industry's 15th Five-Year Plan, which for the first time designates the pharmaceutical industry as a 'national emerging pillar industry' and sets a core target for China's biomedical R&D and application to rank among the world's top by 2030. Recent institutional research reports highlight that the plan introduces a standalone section on 'precision diagnostics,' targets over 200 innovative medical device approvals within five years, and systematically deploys frontier areas such as AI-driven drug development, nuclide diagnostics and therapy, and brain-computer interfaces. Analysts believe the policy represents a comprehensive upgrade in strategic positioning, quantitative targets, and detailed pathways, far exceeding the previous Five-Year Plan. The reports note that innovative drug companies with first-in-class or best-in-class pipelines and international clinical capabilities, as well as contract research organizations (CXOs) deeply integrated into global innovation, will directly benefit from accelerated industrialization and expanded orders. AI drug development platforms with real pipeline progress are also expected to gain both capital and policy recognition.
Read sourceChina Innovation Drug ETFs Rise as New Five-Year Plan Boosts Sector
Innovation drug ETFs in China saw broad gains, with the Sci-Tech Innovation Drug ETFs from both Harvest and Guotai rising nearly 2%. The innovation drug index has risen for six consecutive trading days. The surge follows the official release of the pharmaceutical industry's '15th Five-Year Plan', which for the first time designates the pharmaceutical industry as a 'national emerging pillar industry' and sets a core goal for China's biomedical R&D and application to rank among the world's top tier by 2030. Recent institutional research reports highlight that the plan elevates 'precision diagnosis and treatment' to an independent section for the first time, targets over 200 innovative medical devices to be approved within five years, and systematically deploys frontier areas such as AI-driven drug development, nuclide diagnostics and therapy, and brain-computer interfaces. Analysts believe the policy represents a comprehensive upgrade in strategic positioning, quantitative targets, and detailed pathways, far exceeding the previous five-year plan. The reports note that innovative drug companies with first-in-class or best-in-class pipelines and global clinical capabilities, as well as CXO firms deeply integrated into the global innovation division of labor, will directly benefit from accelerated industrialization and expanded orders. AI drug development platforms with real pipeline progress are also expected to gain both capital and policy recognition.
Read sourceChina Innovative Drug ETFs Rise as New Five-Year Plan Boosts Sector
Innovative drug exchange-traded funds (ETFs) in China saw broad gains, with the Sci-Tech Innovation Innovative Drug ETFs from both Harvest and Guotai rising nearly 2%. The innovative drug index extended its rally to a sixth consecutive session. The rally follows the official release of the pharmaceutical industry's 15th Five-Year Plan, which for the first time designates the pharmaceutical industry as a 'national emerging pillar industry' and sets a core target for China's biomedical R&D and application to rank among the world's top tier by 2030. Recent institutional research reports note that the plan introduces a standalone section on 'precision diagnosis and treatment,' targets over 200 innovative medical device approvals within five years, and systematically deploys frontier areas such as AI-driven drug development, nuclide-based diagnostics and therapy, and brain-computer interfaces. Analysts believe the policy represents a comprehensive upgrade in strategic positioning, quantitative targets, and specific pathways, far exceeding the previous Five-Year Plan. The reports indicate that innovative drug companies with first-in-class or best-in-class pipelines and international clinical capabilities, as well as contract research organizations (CXOs) deeply integrated into global innovation, will directly benefit from accelerated industrialization and expanded orders. AI drug development platforms with real pipeline progress are also expected to gain both capital and policy recognition.
Read sourceChina's Innovative Drug ETFs Rise as New Five-Year Plan Boosts Sector
Innovative drug exchange-traded funds (ETFs) in China saw broad gains, with the Sci-Tech Innovation Innovative Drug ETFs from both Harvest and Guotai rising nearly 2%. The innovative drug index extended its winning streak to six consecutive sessions. The rally follows the official release of the pharmaceutical industry's '15th Five-Year Plan,' which for the first time designates the pharmaceutical industry as a 'national emerging pillar industry' and sets a core target for China's biomedical R&D and application to rank among the world's top by 2030. Recent research reports cited in the article note that the plan introduces a standalone section on 'precision diagnosis and treatment,' targets over 200 new innovative medical devices to be approved within five years, and systematically outlines frontier directions including AI-driven drug development, radionuclide diagnostics, and brain-computer interfaces. Analysts believe the policy represents a comprehensive upgrade in strategic positioning, quantitative targets, and specific pathways, far exceeding the previous '14th Five-Year Plan.' The reports suggest that innovative drug companies with first-in-class or best-in-class pipelines and international clinical capabilities, as well as contract research organizations (CXOs) deeply integrated into global innovation, will directly benefit from accelerated industrialization and expanded orders. AI drug development platforms with active pipelines are also expected to gain both capital and policy support.
Read source